• Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • MDnews
  • About [‘mediPr]
  • HER2 Explorer
  • TROP Tool
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

14 June 2018/0 Comments/in US FDA Onc\Haem Approvals, Gynaecological Cancer, Oncology, Chemotherapy, Targeted Therapies/by scienterrific

 

  • On June 13, 2018, the FDA approved bevacizumab (AvastinⓇ, Genentech, Inc.) in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab for use after surgical resection in patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Tags: epithelial ovarian, peritoneal cancer, Roche, surgery, FDA, bevacizumab, carboplatin, Genentech, Avastin, fallopian tube, paclitaxel
Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
0 0 scienterrific https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png scienterrific2018-06-14 22:56:042018-06-14 22:56:04Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
You might also like
Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
Nivolumab approved for sorafenib-refractory HCC
Pembrolizumab and atezolizumab USPIs updated by FDA
Cabozantinib FDA approved in HCC patients failing sorafenib
Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
Pembrolizumab approved for advanced gastric cancer
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Categories

Newsletter


 [‘mediPr] | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | CORTiX AI for Medical Science | Dub-Dub Subtitle Generation
© 2016-2026 MediPaper Medical Communications Ltd. | Website by [’mediPr] Sydney | Singapore | Hong Kong | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
Link to: FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients Link to: FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patien... Link to: ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised Link to: ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
Scroll to top Scroll to top Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only